Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod vs Fluocinonide in Early Stage CTCL
NCT02301494Withdrawn
- Sponsor
- Rochester General Hospital
- Start
- Apr 2020
- Primary completion
- Apr 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
01
Overview
Randomised, open-label trial of imiquimod in mycosis fungoides (MF) (2 arms), sponsored by Rochester General Hospital. Primary endpoint: Response Rate between baseline and week 16. Planned start Apr 2020; status: withdrawn.
02
Drugs
imiquimod
03
Conditions
mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT02301494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02301494.